Loading...

REVA Medical

ASX:RVA
Snowflake Description

Slightly overvalued with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RVA
ASX
A$71M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

REVA Medical, Inc., a medical device company, focuses on the development and commercialization of polymer-based bioresorbable products for vascular applications. The last earnings update was 164 days ago. More info.


Add to Portfolio Compare Print
  • REVA Medical has significant price volatility in the past 3 months.
RVA Share Price and Events
7 Day Returns
0%
ASX:RVA
3.4%
AU Medical Equipment
0.7%
AU Market
1 Year Returns
-55.3%
ASX:RVA
-3.4%
AU Medical Equipment
4.7%
AU Market
RVA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
REVA Medical (RVA) 0% 0% -15% -55.3% -83.5% 9.7%
AU Medical Equipment 3.4% 0.5% 0.7% -3.4% 39.3% 105.3%
AU Market 0.7% 1.1% 6.5% 4.7% 17.5% 4.9%
1 Year Return vs Industry and Market
  • RVA underperformed the Medical Equipment industry which returned -3.4% over the past year.
  • RVA underperformed the Market in Australia which returned 4.7% over the past year.
Price Volatility
RVA
Industry
5yr Volatility vs Market

Value

 Is REVA Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for REVA Medical. This is due to cash flow or dividend data being unavailable. The share price is A$0.17.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for REVA Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are REVA Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:RVA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $0.04
ASX:RVA Share Price ** ASX (2019-02-15) in AUD A$0.17
ASX:RVA Share Price converted to USD reporting currency Exchange rate (AUD/ USD) 0.715 $0.12
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 33.38x
Australia Market PE Ratio Median Figure of 545 Publicly-Listed Companies 16.18x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of REVA Medical.

ASX:RVA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:RVA Share Price ÷ EPS (both in USD)

= 0.12 ÷ 0.04

3.06x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • REVA Medical is good value based on earnings compared to the AU Medical Equipment industry average.
  • REVA Medical is good value based on earnings compared to the Australia market.
Price based on expected Growth
Does REVA Medical's expected growth come at a high price?
Raw Data
ASX:RVA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 3.06x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.62x
Australia Market PEG Ratio Median Figure of 361 Publicly-Listed Companies 1.38x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for REVA Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on REVA Medical's assets?
Raw Data
ASX:RVA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $-0.18
ASX:RVA Share Price * ASX (2019-02-15) in AUD A$0.17
ASX:RVA Share Price converted to USD reporting currency Exchange rate (AUD/ USD) 0.715 $0.12
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.73x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.68x
ASX:RVA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:RVA Share Price ÷ Book Value per Share (both in USD)

= 0.12 ÷ -0.18

-0.69x

* Primary Listing of REVA Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • REVA Medical has negative assets, we can't compare the value of its assets to the AU Medical Equipment industry average.
X
Value checks
We assess REVA Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. REVA Medical has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is REVA Medical expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
105.5%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is REVA Medical expected to grow at an attractive rate?
  • Unable to compare REVA Medical's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare REVA Medical's earnings growth to the Australia market average as no estimate data is available.
  • REVA Medical's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:RVA Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:RVA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 105.5%
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.6%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:RVA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:RVA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 20 1
2019-12-31 8 1
2018-12-31 3 1
ASX:RVA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 0 -16 16
2018-06-30 0 -18 31
2018-03-31 0 -19 29
2017-12-31 0 -19 7
2017-09-30 0 -20 22
2017-06-30 -20 -8
2017-03-31 -20 -12
2016-12-31 -21 -54
2016-09-30 -21 -100
2016-06-30 -21 -110
2016-03-31 -20 -100
2015-12-31 -19 -83

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if REVA Medical is high growth as no earnings estimate data is available.
  • REVA Medical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:RVA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from REVA Medical Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:RVA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2019-12-31
2018-12-31
ASX:RVA Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 0.04
2018-06-30 0.08
2018-03-31 0.07
2017-12-31 0.02
2017-09-30 0.05
2017-06-30 -0.02
2017-03-31 -0.03
2016-12-31 -0.13
2016-09-30 -0.24
2016-06-30 -0.29
2016-03-31 -0.27
2015-12-31 -0.24

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if REVA Medical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess REVA Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
REVA Medical has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has REVA Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare REVA Medical's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • REVA Medical has delivered over 20% year on year earnings growth in the past 5 years.
  • REVA Medical's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • REVA Medical's 1-year earnings growth is negative, it can't be compared to the AU Medical Equipment industry average.
Earnings and Revenue History
REVA Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from REVA Medical Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:RVA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 0.27 16.39 12.81 8.53
2018-06-30 0.19 31.48 11.68 9.90
2018-03-31 0.10 29.05 10.52 10.47
2017-12-31 0.05 7.13 9.33 12.00
2017-09-30 0.02 22.17 8.65 13.38
2017-06-30 -7.82 8.90 14.50
2017-03-31 -11.88 9.29 16.08
2016-12-31 -54.10 9.38 17.40
2016-09-30 -99.52 8.73 18.99
2016-06-30 -110.44 8.40 19.18
2016-03-31 -100.04 7.60 18.58
2015-12-31 -82.59 8.00 15.97
2015-09-30 -86.90 6.64 15.27
2015-06-30 -56.43 6.37 13.56
2015-03-31 -67.12 6.66 12.70
2014-12-31 -51.04 7.47 14.08
2014-09-30 -24.26 8.74 15.22
2014-06-30 -27.05 9.48 17.52
2014-03-31 -28.87 9.69 18.89
2013-12-31 -27.92 9.40 18.45
2013-09-30 -26.50 9.16 17.20
2013-06-30 -25.14 9.00 16.14
2013-03-31 -24.41 8.85 15.58
2012-12-31 -23.78 8.68 15.19
2012-09-30 -23.22 8.36 14.97
2012-06-30 -22.04 8.19 14.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if REVA Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • REVA Medical used its assets more efficiently than the AU Medical Equipment industry average last year based on Return on Assets.
  • It is difficult to establish if REVA Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess REVA Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
REVA Medical has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is REVA Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up REVA Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • REVA Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • REVA Medical's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of REVA Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • REVA Medical has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from REVA Medical Company Filings, last reported 6 months ago.

ASX:RVA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 -73.27 66.21 7.09
2018-06-30 -65.12 63.46 10.87
2018-03-31 -68.30 71.54 14.86
2017-12-31 -92.81 99.37 20.01
2017-09-30 -94.02 105.70 24.08
2017-06-30 -99.28 116.78 29.15
2017-03-31 -87.26 83.52 1.71
2016-12-31 -89.59 91.66 6.67
2016-09-30 -106.10 113.48 11.55
2016-06-30 -82.84 96.21 16.55
2016-03-31 -80.17 99.17 22.07
2015-12-31 -80.56 75.37 16.90
2015-09-30 -76.23 57.54 12.34
2015-06-30 -42.51 43.05 16.88
2015-03-31 -49.19 49.99 21.58
2014-12-31 -26.45 37.78 26.81
2014-09-30 7.48 0.00 6.30
2014-06-30 11.07 0.00 9.72
2014-03-31 14.86 0.00 14.03
2013-12-31 20.83 0.00 20.72
2013-09-30 27.51 0.00 27.21
2013-06-30 33.68 0.00 33.01
2013-03-31 39.28 0.00 38.52
2012-12-31 44.63 0.00 44.10
2012-09-30 50.04 0.00 49.56
2012-06-30 54.94 0.00 52.78
  • REVA Medical has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if REVA Medical's debt level has increased considering it has negative shareholder equity.
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on REVA Medical's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess REVA Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. REVA Medical has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is REVA Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from REVA Medical dividends. Estimated to be 0% next year.
If you bought A$2,000 of REVA Medical shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate REVA Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate REVA Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:RVA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:RVA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as REVA Medical has not reported any payouts.
  • Unable to verify if REVA Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of REVA Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as REVA Medical has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of REVA Medical's dividends in 3 years as they are not expected to pay a notable one for Australia.
X
Income/ dividend checks
We assess REVA Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can REVA Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. REVA Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of REVA Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • REVA Medical has no CEO, or we have no data on them.
Management Team Tenure

Average tenure and age of the REVA Medical management team in years:

0.3
Average Tenure
51
Average Age
  • The average tenure for the REVA Medical management team is less than 2 years, this suggests a new team.
Management Team

Jeff Anderson

TITLE
President
COMPENSATION
$741K
AGE
51
TENURE
0.1 yrs

Bob Stockman

TITLE
Co-Founder & Director
COMPENSATION
$118K
AGE
64
TENURE
21.3 yrs

Leigh Elkolli

TITLE
CFO, Principal Accounting Officer
AGE
46
TENURE
0.3 yrs

Jessica Earley

TITLE
Vice President of Operations & Product Development
TENURE
0.3 yrs

Cheryl Liberatore

TITLE
Director of Communications

Alexandre Abizaid

TITLE
Co-Principal Investigator for Restore II Clinical Trial & Member of Scientific Advisory Board

David Muller

TITLE
Co-Principal Investigator of Restore II Clinical Trial
TENURE
6.6 yrs

Moni Stein

TITLE
Key Consultant

Paul Teirstein

TITLE
Key Consultant

Joachim Kohn

TITLE
Key Consultant
Board of Directors Tenure

Average tenure and age of the REVA Medical board of directors in years:

8.8
Average Tenure
66.5
Average Age
  • The tenure for the REVA Medical board of directors is about average.
Board of Directors

Ray Larkin

TITLE
Chairman of the Board
COMPENSATION
$28K
AGE
69
TENURE
1.6 yrs

Bob Stockman

TITLE
Co-Founder & Director
COMPENSATION
$118K
AGE
64
TENURE
20.3 yrs

Alexandre Abizaid

TITLE
Co-Principal Investigator for Restore II Clinical Trial & Member of Scientific Advisory Board

Brian Dovey

TITLE
Director
COMPENSATION
$137K
AGE
76
TENURE
17.8 yrs

Gregg Stone

TITLE
Member of Scientific Advisory Board
AGE
61

Rob Thomas

TITLE
Independent Non-Executive Director
COMPENSATION
$130K
AGE
73
TENURE
8.8 yrs

Ross Breckenridge

TITLE
Non-Executive Director
COMPENSATION
$124K
AGE
48
TENURE
4.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
02. Jul 18 Buy Robert Thomas Individual 29. Jun 18 29. Jun 18 163,596 A$0.21 A$33,848
02. Jul 18 Buy Stephen Oesterle Individual 29. Jun 18 29. Jun 18 163,596 A$0.21 A$33,848
02. Jul 18 Buy Charles Larkin Individual 29. Jun 18 29. Jun 18 196,315 A$0.21 A$40,617
02. Jul 18 Buy Robert Stockman Individual 29. Jun 18 29. Jun 18 327,191 A$0.21 A$67,696
17. Jun 18 Buy Robert Thomas Individual 14. Jun 18 15. Jun 18 50,000 A$0.25 A$11,941
03. Jun 18 Buy Robert Thomas Individual 31. May 18 01. Jun 18 50,000 A$0.28 A$13,750
X
Management checks
We assess REVA Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. REVA Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is REVA Medical, Inc.'s (ASX:RVA) P/E Ratio Really That Good?

REVA Medical has a P/E ratio of 3.62, based on the last twelve months. … Price to Earnings Ratio = Price per Share (in the reporting currency) ÷ Earnings per Share (EPS) … P/E of 3.62 = $0.14 (Note: this is the share price in the reporting currency, namely, USD ) ÷ $0.040

Simply Wall St -

Should You Be Tempted To Buy REVA Medical Inc (ASX:RVA) At Its Current PE Ratio?

REVA Medical Inc (ASX:RVA) trades with a trailing P/E of 2, which is lower than the industry average of 25.5. … While RVA might seem like an attractive stock to buy, it is important to understand the assumptions behind the P/E ratio before you make any investment decisions. … I will explain what the P/E ratio is as well as what you should look out for when using it

Simply Wall St -

Should You Be Tempted To Buy REVA Medical Inc (ASX:RVA) At Its Current PE Ratio?

and want to better understand how you can grow your money by investing in REVA Medical Inc (ASX:RVA). … REVA Medical Inc (ASX:RVA) is trading with a trailing P/E of 2.2x, which is lower than the industry average of 49.1x. … Although some investors may jump to the conclusion that this is a great buying opportunity, understanding the assumptions behind the P/E ratio might change your mind

Simply Wall St -

Is REVA Medical Inc (ASX:RVA) Still A Cheap Healthcare Stock?

Today, I will analyse the industry outlook, and also determine whether REVA Medical is a laggard or leader relative to its healthcare sector peers. … As an industry laggard, REVA Medical may be a cheaper stock relative to its peers. … On the stock-level, REVA Medical is trading at a lower PE ratio of 2.88x, making it cheaper than the average healthcare equipment stock.

Simply Wall St -

Who Are REVA Medical Inc's (ASX:RVA) Major Shareholders?

View our latest analysis for REVA Medical ASX:RVA Ownership_summary Apr 26th 18 Institutional Ownership In RVA's case, institutional ownership stands at 21.55%, significant enough to cause considerable price moves in the case of large institutional transactions, especially when there is a low level of public shares available on the market to trade. … I am going to further examine RVA's ownership structure to check how other major shareholders can affect its investment case. … Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital.

Simply Wall St -

REVA Medical Inc (ASX:RVA): Are Analysts’ Earnings Forecast Signalling Trouble Ahead?

Investors may find it useful to understand how market analysts predict REVA Medical's earnings growth outlook over the next couple of years and whether the future looks brighter. … View our latest analysis for REVA Medical Market analysts' prospects for next year seems pessimistic, with earnings turning into a loss in 2019. … This means that, we can presume REVA Medical will chip away at a rate of -40.72% every year for the next couple of years.

Simply Wall St -

Is It Time To Buy REVA Medical Inc (ASX:RVA) Based Off Its PE Ratio?

It compares a stock’s price per share to the stock’s earnings per share. … Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for RVA Price per share = $0.28 Earnings per share = $0.017 ∴ Price-Earnings Ratio = $0.28 ÷ $0.017 = 16x The P/E ratio isn’t a metric you view in isolation and only becomes useful when you compare it against other similar companies. … For example, if you inadvertently compared lower risk firms with RVA, then investors would naturally value RVA at a lower price since it is a riskier investment.

Simply Wall St -

Who Are The Major Shareholders In REVA Medical Inc (ASX:RVA)?

This size of ownership may not be enough to sway a policy decision in their favour, but they can still make a collective impact on company policies if it aligns with other large shareholders. … Private Company Ownership Potential investors in RVA should also look at another important group of investors: private companies, with a stake of 1.33%, who are primarily invested because of strategic and capital gain interests. … However, an ownership of this size may be relatively insignificant, meaning that these shareholders may not have the potential to influence RVA's business strategy.

Simply Wall St -

Is REVA Medical Inc (ASX:RVA) A Buy At Its Current PE Ratio?

It compares a stock’s price per share to the stock’s earnings per share. … Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for RVA Price per share = 0.52 Earnings per share = 0.053 ∴ Price-Earnings Ratio = 0.52 ÷ 0.053 = 9.9x The P/E ratio isn’t a metric you view in isolation and only becomes useful when you compare it against other similar companies. … RVA’s P/E of 9.9x is lower than its industry peers (28.3x), which implies that each dollar of RVA’s earnings is being undervalued by investors.

Simply Wall St -

Company Info

Description

REVA Medical, Inc., a medical device company, focuses on the development and commercialization of polymer-based bioresorbable products for vascular applications. The company offers Fantom Encore, a bioresorbable vascular scaffold for the treatment of coronary artery disease; and MOTIV bioresorbable vascular scaffold for the treatment of below-the-knee peripheral artery disease. It sells Fantom Encore in Germany, Switzerland, Austria, the Netherlands, Belgium, Luxembourg, Italy, and Turkey. The company was formerly known as MD3, Inc. and changed its name to REVA Medical, Inc. in March 2002. REVA Medical, Inc. was founded in 1998 and is headquartered in San Diego, California.

Details
Name: REVA Medical, Inc.
RVA
Exchange: ASX
Founded: 1998
A$70,561,503
415,067,670
Website: http://www.revamedical.com
Address: REVA Medical, Inc.
5751 Copley Drive,
San Diego,
California, 92111,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX RVA SHS CH DP 1/10 Australian Securities Exchange AU AUD 23. Dec 2010
OTCPK RVAL.L SHS CH DP 1/10 Pink Sheets LLC US USD 23. Dec 2010
DB RV9C SHS CH DP 1/10 Deutsche Boerse AG DE EUR 23. Dec 2010
CHIA RVA SHS CH DP 1/10 Chi-X Australia AU AUD 23. Dec 2010
Number of employees
Current staff
Staff numbers
51
REVA Medical employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 10:34
End of day share price update: 2019/02/15 00:00
Last estimates confirmation: 2019/03/06
Last earnings filing: 2018/11/06
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.